CD38 (Mouse) Fluorogenic Assay Kit (Cyclase Activity)

Catalog #
78285
$765 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The CD38 (Mouse) Inhibitor Screening Assay Kit (Cyclase Activity) is designed to measure the cyclase activity of CD38 (mouse) for screening and profiling applications. The CD38 assay kit comes in a convenient 96-well format, with purified recombinant CD38 enzyme, its substrate nicotinamide guanine dinucleotide (NGD+), and CD38 assay buffer for 100 enzyme reactions. In addition, the kit includes the CD38 inhibitor quercetin for use as an inhibitor control.

Assay Principle

Need us to run inhibitor screens or profile your compounds against CD38 (Mouse) (Cyclase Activity)? Check out our Immunotherapy Biochemical Screening Services.

Synonyms
cluster of differentiation 38, cyclic ADP ribose cyclase, activity assay kit
Product Info
Storage and Usage
Citations
Assay Kit Format
Fluorogenic
Species
Mouse
Supplied As
The CD38 assay kit comes in a convenient 96-well format, with purified recombinant CD38 enzyme, its substrate nicotinamide guanine dinucleotide (NGD+), and CD38 assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

Adjustable micropipettor and sterile tips
Fluorescent microplate reader
Rotating or rocker platform

Format
Catalog # Name Amount Storage
79070 CD38, His-Tag (Mouse), HiP™ 2 x 1 µg -80°C
  3x CD38 cyclase assay buffer 4 ml -20°C
  CD38 substrate NGD+ 50 µl -20°C
  Quercetin (50 mM in DMSO) 100 µl -20°C
79685 Black 96-well plate 1 Room Temp.

*The initial concentration of CD38 is lot-specific and will be indicated on the tube containing the protein.

Background

CD38, a differentiation antigen of B lymphocytes, is a type II integral membrane protein. It is also known as ADP-ribosyl cyclase and nicotinamide adenine dinucleotide (NAD+) glycohydrolase. Through its production of cyclic ADP-ribose, CD38 modulates calcium-mediated signal transduction in various cells, including pancreatic b cells, where it regulates insulin secretion. CD38 is a prognostic biomarker for acute B lymphoblastic leukemia, and anti-CD38 antibodies are in clinical trials as therapeutics for multiple myeloma.

References

Wei, W., et al., World J. Biol. Chem. 2014, 5(1):58-67.